Literature DB >> 28631079

Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study.

Wataru Gonoi1, Takana Yamakawa Hayashi2, Hidemi Okuma2, Masaaki Akahane2,3, Yousuke Nakai4, Suguru Mizuno4, Ryosuke Tateishi4, Hiroyuki Isayama4, Kazuhiko Koike4, Kuni Ohtomo2.   

Abstract

OBJECTIVES: To investigate the radiological findings prognostic for the development of pancreatic adenocarcinoma in a cohort of patients with hepatocellular carcinoma, using multiphasic computed tomography (CT).
METHODS: A case-cohort study performed in a single university hospital. A database of patients who received hepatocellular carcinoma (HCC) treatment and trimonthly follow-up with four-phase dynamic CT was used (n = 1848). The cohort group was randomly extracted from the database (n = 103). The case group comprised nine patients from the database who developed pancreatic adenocarcinoma. The radiological findings were assessed during follow-up (average, 32 months).
RESULTS: The incidence of pancreatic mass, inhomogeneous parenchyma, loss of fatty marbling and main pancreatic duct dilatation gradually increased from 4 to 13 months before the diagnosis of pancreatic adenocarcinoma. There was a significantly higher incidence of pancreatic mass, inhomogeneous parenchyma and loss of fatty marbling on CT at baseline (average, 34 months before diagnosis) in the case group compared with the cohort group (P values < 0.01) and those findings at baseline were revealed as prognostic factors for pancreatic carcinogenesis, respectively (log-rank test, P values < 0.001).
CONCLUSIONS: Several radiological findings observed on multiphasic CT can assist in predicting pancreatic carcinogenesis well in advance. KEY POINTS: • Pancreatic findings in multiphasic CT help predict development of pancreatic adenocarcinoma. • Key findings are mass, inhomogeneous parenchyma and loss of fatty marbling. • Those findings were observed 34 months before confirmed diagnosis of adenocarcinoma. • Those findings were prognostic factors for pancreatic carcinogenesis.

Entities:  

Keywords:  Adenocarcinoma; Pancreas; Prognosis; Radiology; Screening

Mesh:

Substances:

Year:  2017        PMID: 28631079     DOI: 10.1007/s00330-017-4895-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  35 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  Multidetector CT of the pancreas.

Authors:  Raj Mohan Paspulati
Journal:  Radiol Clin North Am       Date:  2005-11       Impact factor: 2.303

3.  Validation of the 2012 International Consensus Guidelines Using Computed Tomography and Magnetic Resonance Imaging: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Nieun Seo; Jae Ho Byun; Jin Hee Kim; Hyoung Jung Kim; Seung Soo Lee; Ki Byung Song; Song-Cheol Kim; Duck Jong Han; Seung-Mo Hong; Moon-Gyu Lee
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

4.  Pancreas divisum as a predisposing factor for chronic and recurrent idiopathic pancreatitis: initial in vivo survey.

Authors:  Wataru Gonoi; Hiroyuki Akai; Kazuchika Hagiwara; Masaaki Akahane; Naoto Hayashi; Eriko Maeda; Takeharu Yoshikawa; Minoru Tada; Kansei Uno; Hiroshi Ohtsu; Kazuhiko Koike; Kuni Ohtomo
Journal:  Gut       Date:  2011-02-15       Impact factor: 23.059

5.  Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas.

Authors:  D J Brat; K D Lillemoe; C J Yeo; P B Warfield; R H Hruban
Journal:  Am J Surg Pathol       Date:  1998-02       Impact factor: 6.394

6.  Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer.

Authors:  P Berthélemy; M Bouisson; J Escourrou; N Vaysse; J L Rumeau; L Pradayrol
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

7.  Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Authors:  Ioannis T Konstantinidis; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers; David P Ryan; Jennifer A Wargo; Keith D Lillemoe; Cristina R Ferrone
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

8.  Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis.

Authors:  Mario Pelaez-Luna; Naoki Takahashi; Joel G Fletcher; Suresh T Chari
Journal:  Am J Gastroenterol       Date:  2007-10       Impact factor: 10.864

9.  The incidental asymptomatic pancreatic lesion: nuisance or threat?

Authors:  Teviah Sachs; Wande B Pratt; Mark P Callery; Charles M Vollmer
Journal:  J Gastrointest Surg       Date:  2009-01-08       Impact factor: 3.452

10.  Indicative findings of pancreatic cancer in prediagnostic CT.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Jin-Young Choi; Hye-Suk Hong; Yong Eun Chung; Joon Seok Lim
Journal:  Eur Radiol       Date:  2009-05-05       Impact factor: 5.315

View more
  6 in total

1.  Early detection and imaging strategies to reveal and target developing pancreatic cancer.

Authors:  Howard C Crawford; Michael B Wallace; Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2020-01-27       Impact factor: 4.512

2.  Development of pancreatic cancer during observation for hepatocellular carcinoma: A retrospective cohort study.

Authors:  Wataru Gonoi; Hidemi Okuma; Takana Y Hayashi; Masaaki Akahane; Yousuke Nakai; Ryosuke Tateishi; Suguru Mizuno; Yuichi Suzuki; Minoru Mitsuda; Kanako Matsuda; Keiichi Nakagawa; Hiroyuki Isayama; Kiyoshi Miyagawa; Kazuhiko Koike; Osamu Abe
Journal:  Saudi J Gastroenterol       Date:  2019 Nov-Dec       Impact factor: 2.485

3.  Application of Radiomics Analysis Based on CT Combined With Machine Learning in Diagnostic of Pancreatic Neuroendocrine Tumors Patient's Pathological Grades.

Authors:  Tao Zhang; YueHua Zhang; Xinglong Liu; Hanyue Xu; Chaoyue Chen; Xuan Zhou; Yichun Liu; Xuelei Ma
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

Review 4.  Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma.

Authors:  Hiromitsu Hayashi; Norio Uemura; Kazuki Matsumura; Liu Zhao; Hiroki Sato; Yuta Shiraishi; Yo-Ichi Yamashita; Hideo Baba
Journal:  World J Gastroenterol       Date:  2021-11-21       Impact factor: 5.742

Review 5.  Application of artificial intelligence to pancreatic adenocarcinoma.

Authors:  Xi Chen; Ruibiao Fu; Qian Shao; Yan Chen; Qinghuang Ye; Sheng Li; Xiongxiong He; Jinhui Zhu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

6.  Pancreatic Fat Infiltration Is Associated with a Higher Risk of Pancreatic Ductal Adenocarcinoma.

Authors:  Vishal Desai; Kevin Patel; Ravi Sheth; Usman Barlass; Yuet-Ming Chan; Joy Sclamberg; Faraz Bishehsari
Journal:  Visc Med       Date:  2020-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.